Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials.

PubWeight™: 1.46‹?› | Rank: Top 5%

🔗 View Article (PMC 3815514)

Published in Menopause on March 01, 2014

Authors

Marianne Canonico1, Geneviève Plu-Bureau, Mary Jo O'Sullivan, Marcia L Stefanick, Barbara Cochrane, Pierre-Yves Scarabin, Joann E Manson

Author Affiliations

1: From the 1Hormones and Cardiovascular Disease, Center for Research in Epidemiology and Population Health, Villejuif, France; 2Université Paris Sud, UMRS 1018, Villejuif, France; 3Paris Descartes University and Cochin-Port Royal Hospital, Paris, France; 4Department of Obstetrics and Gynecology, Miller School of Medicine, University of Miami, Miami, FL; 5Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, CA; 6University of Washington School of Nursing, Seattle, WA; and 7Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Articles cited by this

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med (1991) 7.62

Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA (2003) 4.72

Number of pregnancies and the subsequent risk of cardiovascular disease. N Engl J Med (1993) 4.30

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2000) 4.29

Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ (2011) 3.97

Estrogen plus progestin and risk of venous thrombosis. JAMA (2004) 3.46

Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause (2012) 3.32

Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ (2011) 3.25

Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost (2000) 3.21

Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation (2007) 3.17

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ (2011) 2.98

Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause (2006) 2.64

Premature menopause or early menopause: long-term health consequences. Maturitas (2009) 2.33

Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab (2009) 2.32

An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med (2000) 2.28

Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost (2006) 2.17

Age at menopause as a risk factor for cardiovascular mortality. Lancet (1996) 1.94

Reproductive factors and risk of myocardial infarction. Am J Epidemiol (1992) 1.94

Age at natural menopause and risk of cardiovascular disease. Arch Intern Med (1999) 1.90

Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet (2003) 1.88

Premature menopause or early menopause and risk of ischemic stroke. Menopause (2012) 1.84

Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol (2003) 1.79

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ (2008) 1.78

Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol (2009) 1.73

Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA (2004) 1.70

Risk factors for mortality in the nurses' health study: a competing risks analysis. Am J Epidemiol (2010) 1.61

Menopause and modifiable coronary heart disease risk factors: a population based study. Maturitas (2009) 1.61

Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol (2002) 1.58

Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ (1997) 1.55

Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost (2012) 1.52

Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med (2006) 1.50

The greatest threat to women's health. Lancet (2003) 1.40

Relationships of age at menarche and menopause, and reproductive year with mortality from cardiovascular disease in Japanese postmenopausal women: the JACC study. J Epidemiol (2006) 1.38

Correlates and consequences of venous thromboembolism: The Iowa Women's Health Study. Am J Public Health (2009) 1.18

Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf (2012) 1.15

Risk of ischemic stroke and lifetime estrogen exposure. Neurology (2007) 1.09

Number of pregnancies and risk for stroke and stroke subtypes. Arch Neurol (1997) 1.04

Reproductive risk factors for cardiovascular disease mortality among postmenopausal women in Korea: the Kangwha Cohort Study, 1985-2005. Menopause (2011) 1.04

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause (2011) 1.03

Age at menopause, body mass index, and the risk of colorectal cancer mortality in the Dutch Diagnostisch Onderzoek Mammacarcinoom (DOM) cohort. Epidemiology (2000) 0.99

Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol (2010) 0.97

The association of reproductive history with all-cause and cardiovascular mortality in older women: the Rancho Bernardo Study. Fertil Steril (2011) 0.96

Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort. Breast Cancer Res Treat (1999) 0.96

Menopause with cardiovascular disease and its risk factors among rural Chinese women in Beijing: a population-based study. Maturitas (2012) 0.95

Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost (2010) 0.93

Lifetime estrogen exposure versus age at menopause as mortality predictor. Maturitas (2002) 0.93

Parity and total, ischemic heart disease and stroke mortality. The Adventist Health Study, 1976-1988. Eur J Epidemiol (2011) 0.89

Early age at menarche associated with increased all-cause mortality. Eur J Epidemiol (2011) 0.89

Early age at menopause is associated with increased risk of dementia and mortality in women with Down syndrome. J Alzheimers Dis (2010) 0.88

Parity, age at first birth, and risk of death from pancreatic cancer: evidence from a cohort in Taiwan. Pancreas (2010) 0.88

Premature menopause increases cardiovascular risk. Climacteric (2009) 0.85

Progesterone receptor expression in human saphenous veins. Circulation (1995) 0.83

Reproductive history, hormone replacement, and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. Br J Haematol (2010) 0.78

Articles by these authors

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32

Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44

Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09

Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50

Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med (2004) 9.62

Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57

Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73

Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70

Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77

National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA (2013) 7.19

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12

Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87

Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46

Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA (2007) 6.02

Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75

Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 5.59

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA (2004) 5.35

Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol (2008) 5.28

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22

Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80

Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care (2006) 4.62

Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42

Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA (2003) 4.03

Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91

Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol (2007) 3.88

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85

Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60

Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med (2004) 3.59

Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr (2005) 3.55

A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials (2002) 3.41

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33

Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27

Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation (2007) 3.17

Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17

Mortality and cardiac and vascular outcomes in extremely obese women. JAMA (2006) 3.09

Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol (2013) 3.08

Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care (2006) 3.06

Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2010) 3.03

Sexual orientation, health risk factors, and physical functioning in the Nurses' Health Study II. J Womens Health (Larchmt) (2004) 3.01

Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med (2011) 3.00

Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97

The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol (2010) 2.96

Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst (2011) 2.84

Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA (2007) 2.81

Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. J Womens Health (Larchmt) (2013) 2.81

Rapid HIV-1 testing during labor: a multicenter study. JAMA (2004) 2.81

Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. BMJ (2011) 2.80

Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79

Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) (2006) 2.77

Prospective study of body mass index and risk of stroke in apparently healthy women. Circulation (2005) 2.73

Physical activity and survival in postmenopausal women with breast cancer: results from the women's health initiative. Cancer Prev Res (Phila) (2011) 2.73

Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. Am J Obstet Gynecol (2006) 2.69

The Women's Health Initiative: The food environment, neighborhood socioeconomic status, BMI, and blood pressure. Obesity (Silver Spring) (2011) 2.50

Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation (2005) 2.49

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst (2013) 2.45

Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension (2008) 2.44

Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes (2012) 2.43

Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab (2002) 2.40

Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med (2013) 2.38

Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care (2007) 2.33

Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. JAMA (2008) 2.32

Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis (2005) 2.30

Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative. J Am Geriatr Soc (2012) 2.30

C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med (2006) 2.22

Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr (2011) 2.21

Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum (2009) 2.19

A prospective study of dairy intake and the risk of type 2 diabetes in women. Diabetes Care (2006) 2.18

Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. Cancer (2013) 2.14

Potato and french fry consumption and risk of type 2 diabetes in women. Am J Clin Nutr (2006) 2.05

Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. BMJ (2013) 2.05

A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes (2004) 2.03

Carbohydrate intake, glycemic index, glycemic load, and dietary fiber in relation to risk of stroke in women. Am J Epidemiol (2005) 2.03

Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci (2009) 2.01

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol (2005) 2.01

A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 2.01

Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women. Am J Epidemiol (2009) 1.98

Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol (2003) 1.98